Determination of in vitro susceptibility of Mycobacterium avium complex isolates to antimycobacterial agents by various methods.
about
A macrophage invasion mechanism for mycobacteria implicating the extracellular domain of CD43Activity of clarithromycin against Mycobacterium avium complex infection in beige miceMIC as a quantitative measurement of the susceptibility of Mycobacterium avium strains to seven antituberculosis drugsComparison of bactericidal activities of streptomycin, amikacin, kanamycin, and capreomycin against Mycobacterium avium and M. tuberculosisIn vitro and in vivo activities of clarithromycin against Mycobacterium aviumMefloquine is active in vitro and in vivo against Mycobacterium avium complexTelithromycin is active against Mycobacterium avium in mice despite lacking significant activity in standard in vitro and macrophage assays and is associated with low frequency of resistance during treatmentActivity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium aviumAmikacin, ciprofloxacin, and imipenem treatment for disseminated Mycobacterium avium complex infection of beige miceIn vitro activities of several new macrolide antibiotics against Mycobacterium avium complexPostantibiotic effects of antituberculosis agents alone and in combinationA bone marrow-derived murine macrophage model for evaluating efficacy of antimycobacterial drugs under relevant physiological conditionsActivities of the benzoxazinorifamycin KRM 1648 and ethambutol against Mycobacterium avium complex in vitro and in macrophagesRifabutin and sparfloxacin but not azithromycin inhibit binding of Mycobacterium avium complex to HT-29 intestinal mucosal cellsRoxithromycin alone and in combination with either ethambutol or levofloxacin for disseminated Mycobacterium avium infections in beige miceActivities of bay Y 3118, levofloxacin, and ofloxacin alone or in combination with ethambutol against Mycobacterium avium complex in vitro, in human macrophages, and in beige miceInfection with Mycobacterium avium induces production of interleukin-10 (IL-10), and administration of anti-IL-10 antibody is associated with enhanced resistance to infection in mice.Potential drug targets for Mycobacterium avium defined by radiometric drug-inhibitor combination techniques.Azithromycin as treatment for disseminated Mycobacterium avium complex in AIDS patients.Fluorescent acid-fast microscopy for measuring phagocytosis of Mycobacterium avium, Mycobacterium intracellulare, and Mycobacterium scrofulaceum by Tetrahymena pyriformis and their intracellular growth.Perspective on animal models: chronic intracellular infections.Identification of Mycobacterium avium genes expressed during in vivo infection and the role of the oligopeptide transporter OppA in virulence.Postantibiotic effect of clarithromycin alone and combined with ethambutol against Mycobacterium avium complexThiosemicarbazole (thiacetazone-like) compound with activity against Mycobacterium avium in miceIn vitro activity of amikacin against Mycobacterium avium.Activities of amikacin, roxithromycin, and azithromycin alone or in combination with tumor necrosis factor against Mycobacterium avium complex.Epidemiology of infection by nontuberculous mycobacteriaIn vitro activity of the antimicrobial peptides human and rabbit defensins and porcine leukocyte protegrin against Mycobacterium tuberculosisEDP-420, a bicyclolide (bridged bicyclic macrolide), is active against Mycobacterium avium.Pharmacokinetics, toxicity, and efficacy of liposomal capreomycin in disseminated Mycobacterium avium beige mouse modelClarithromycin-ciprofloxacin-amikacin for therapy of Mycobacterium avium-Mycobacterium intracellulare bacteremia in patients with AIDS.Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria.The changing pattern of nontuberculous mycobacterial diseaseThe Mycobacterium avium complexRapid broth macrodilution method for determination of MICs for Mycobacterium avium isolates.A subinhibitory concentration of clarithromycin inhibits Mycobacterium avium biofilm formation.Mycobacterial disease associated with HIV infection.Drug susceptibility testing of nontuberculous mycobacteria.The efficiency of the translocation of Mycobacterium tuberculosis across a bilayer of epithelial and endothelial cells as a model of the alveolar wall is a consequence of transport within mononuclear phagocytes and invasion of alveolar epithelial ceIn vitro susceptibility of Mycobacterium kansasii to clarithromycin.
P2860
Q22254624-2113FE29-A859-4923-9A52-0C467489F661Q28327192-E0C048B4-298A-4D31-AD26-1EB310023826Q28339347-E2CA7B63-0FFB-4ADE-AE1E-BD762B6DC6E1Q28340239-2ECDF65A-455D-4872-9BEF-CD6C74FAA2D5Q28342095-12F4A8C8-E921-4E46-AF76-F211EC08A404Q28343464-AEE42528-77E0-4F57-873F-3B49A9D61A69Q28343803-326C988E-700E-4CAD-933B-45168D5FD233Q28345248-69BD5B50-8D67-44C1-A287-44246A1E3D47Q28356424-9E0A9909-D36E-48ED-9066-2C8EFE600214Q28359735-F3D09531-5119-4FDF-BAB9-0034DE4B3609Q28364143-F464C441-59FB-4DA8-BB72-2883877EA34BQ28368663-B637AECE-1DF6-495D-B332-D31E946582C1Q28369151-45F3F9FA-E630-476F-84DF-1594F23B5C94Q28369391-244F585E-4B50-484D-8D5A-28ED1AC4533FQ28379202-6A6E459E-1E03-46C6-B468-A874E1CF1EB5Q28379216-E64294A5-97BD-4E08-B5AE-A49A33F051A6Q33603597-B7C216C0-29AB-4CE6-A41C-2B410269E031Q33760607-F4D10F25-A10B-492E-920B-021728302D26Q33978221-EC1D8487-9BBC-4477-8CBF-17E620F17F8AQ33990388-F2D18B4C-D5C2-4DB1-AEE6-EF7501802779Q34347914-050714E2-73DA-4DE9-A042-2D71B394899CQ34603188-E1F4AC87-83C2-4282-9DC3-DA9EB275329EQ35121082-D0D15ABC-ABBC-477C-B9E2-B08A991EADBFQ35165923-27C3C740-E65A-4A38-B191-885511C67C89Q35249418-D18441E1-E22A-4FD5-BD51-CE7B74977FD9Q35316644-B4AA38C5-28BA-44B1-87A1-CE14A01C6C30Q35370226-4B023D18-A2DB-41E7-A302-DAE9101E7D35Q35475220-8B449416-FCA1-4CD6-9889-46787E75C341Q35759023-4F2D5A58-B468-4F6C-B1D8-C4719A7C23C5Q35822868-A0D53758-F597-4A8E-A3B1-42A0E44587BCQ35885553-17F5F46A-7AB8-47B5-919C-983793158FBCQ36156072-9B4859C4-C500-448C-BCA8-5FE5DA4466A0Q36170798-FC59920D-5E04-47FC-B9B0-542528E86FC0Q36640345-6B16B072-3A3C-4621-ADD5-F60A0E62F9E5Q37133132-CA906196-554C-44B0-9742-C440D06D5425Q37625414-6BA08787-9B97-4A6B-ADD9-1C40F41373A3Q37669831-F8B3D3AF-E3AB-41A9-AD0F-E1156DF23FC4Q38262208-E4D1F292-CD70-47D2-97BE-D845CF60B8BAQ39653495-2EB859AF-6C56-4341-908E-04E67BC61148Q39882632-C116E19C-7605-46E4-BDE8-E97A05F93A8B
P2860
Determination of in vitro susceptibility of Mycobacterium avium complex isolates to antimycobacterial agents by various methods.
description
1987 nî lūn-bûn
@nan
1987 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1987 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1987年の論文
@ja
1987年論文
@yue
1987年論文
@zh-hant
1987年論文
@zh-hk
1987年論文
@zh-mo
1987年論文
@zh-tw
1987年论文
@wuu
name
Determination of in vitro susc ...... ial agents by various methods.
@ast
Determination of in vitro susc ...... ial agents by various methods.
@en
type
label
Determination of in vitro susc ...... ial agents by various methods.
@ast
Determination of in vitro susc ...... ial agents by various methods.
@en
prefLabel
Determination of in vitro susc ...... ial agents by various methods.
@ast
Determination of in vitro susc ...... ial agents by various methods.
@en
P2093
P2860
P356
P1476
Determination of in vitro susc ...... ial agents by various methods.
@en
P2093
C B Inderlied
J K Yamada
P2860
P304
P356
10.1128/AAC.31.11.1697
P407
P577
1987-11-01T00:00:00Z